article thumbnail

470% price increases

World of DTC Marketing

According to AbbVie’s internal data, the company collected nearly $10 billion in Humira net revenue from Medicare Part D between 2010 and 2018. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. Lack of Medicare Negotiation Costing Taxpayers Billions: U.S.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP. Over the same period, similar countries – including Ireland, France, and Germany – have been moving to boosting manufacturing productivity, output, and exports.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Highly Cited Researchers 2021: How nations and institutions foster exceptional performance

Clarivate

These highly cited papers rank in the top 1% by citations for field and year from 2010 – 2020. We’re pleased to showcase some institutions that excel in a competitive global environment, supporting their Highly Cited Researchers in a way that encourages collaboration, facilitates career growth and accelerates highly innovative research.

article thumbnail

UK authority asks for director ban for Alliance Pharma CEO

pharmaphorum

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. ” The action will only be heard if the Competition Appeal Tribunal (CAT) upholds the CMA’s findings against Alliance, it added. .”

Pharma 59
article thumbnail

Novartis knocked back again in bid to block Gilenya generics in US

pharmaphorum

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. After initially upholding the patent in January, the CAFC subsequently ruled in June that it was not valid, opening the door to low-cost competition to Novartis’ third biggest-selling product.

article thumbnail

Global comparator data signal “alarm bells” for UK Government, says APBI

pharmaphorum

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Richard Torbett, chief executive at the Association of the British Pharmaceutical Industry (ABPI) said Life Sciences Competitive Indicators (LSCI) data published last week “ought to ring alarm bells across Government”.

article thumbnail

Supreme court throws Novartis a lifeline for Gilenya defense

pharmaphorum

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US. Gilenya made revenues of $2.8 Sales in the first half of this year fell 19% to $1.16